Medicineworld.org: Archives of colon-cancer-blog
Go Back to the main colon-cancer-blog
Subscribe To Health Blog RSS Feed
Archives Of Colon-cancer-blog From Medicineworld.Org
Erbitux will not be available in Canada
Use of Erbitux to treat colorectal cancer was approved by Health Canada in September of 2005.
The province of Ontario has approved payment for therapy with Erbitux- in the United States for some patients, as per the June 19, 2006 Globe and Mail.
The Colorectal Cancer Association of Canada has spoken out on the lack of access to drugs to treat colorectal cancer in Canada. Drugs, such as Avastin, Erbitux, and Eloxatin have been approved by Health Canada but are not uniformly available across the nation because each province can choose whether or not to pay for the therapys. In some provinces, patients can have the drugs administered if they pay the cost of the medicines themselves.
Thank you Judi........
Posted by: Sue Permalink Source
Suggest your News Item To Medicineworld
We are looking for quality news items that would be interesting to our readers. Now you may suggest the news item from your site to be included at Medicineworld.org. Inclusion of news item at our site get instantaneous attention since the item is illustrated from various blog posts. Addition of pictures to the item adds additional attraction to your news item. Inclusion in the Medicineworld.org site brings quality links and visitors to your site.
If you have an interesting news item related to health, share it with Medicineworld.org and we share it with the world.
Suggest your News Item To Medicineworld........
Posted by: Janet Permalink
Camptosar Important In Metastatic Colorectal Cancer
The predefined analysis of the primary endpoint showed FOLFIRI provided a statistically significant benefit in PFS (8.2 months) when compared with mIFL (6.0 months) or CapeIRI (5.7 months). In addition the median OS for FOLFIRI was 23.1 months, for mIFL - 17.6 months and for CapeIRI - 18.9 months. Though it did not reach statistical significance, there was a trend favoring FOLFIRI. OS benefit reflects all therapies patients may have received, including 2nd and 3rd lines. The most frequent grade 3/4 adverse events in all arms were diarrhea and neutropenia. In general the toxicity profile favored the FOLFIRI arm. Each arm had a secondary randomization to celecoxib or a placebo. In general, celecoxib neither improved efficacy nor reduced chemotherapy toxicity.........
Posted by: Sue Permalink Source
Follow Up Lacking In Colon Cancer Screening
Published in May in the journal Diseases of the Colon & Rectum, the UCLA/VA study is one of the largest reviews of colorectal screening and follow-up patient data to date. The study used data from the VA, the nation's largest integrated health care system. The study waccording toformed as a prelude to a national VA effort, now underway, to improve colorectal cancer screening and suggested the need for better medical follow-through for patients with potential colon cancer.
Study authors took advantage of the VA's ongoing quality improvement program to analyze 39,870 patient records. Overall, 61 percent of eligible VA patients had been screened for colorectal cancer, a rate significantly higher than the national average. Of the screened population, 313 patients had an abnormal FOBT result. Only 59 percent, or 185 patients, of this group received follow-up diagnostic tests such as a colonoscopy or a barium enema. Forty-one percent, or 128 patients, received no follow-up at all in the six months following the FOBT.........
Posted by: Sue Permalink Source
Looking For Participant For An Online Survey Of Cancer Blogs
Deborah S. Chung, Ph.D. who is Assistant Professor at University of Kentucky School of Journalism and Telecommunications has contacted me about an online survey for cancer patients. This is a study about cancer blog use by cancer patients.
The purpose of this study is to describe characteristics of cancer blog users and their motivations for visiting cancer blogs. In addition, this study hopes to assess behavioral changes after using cancer blogs and to draw associations between everyday use of media and use of cancer blogs.
This study will help cancer information seekers and healthcare providers alike understand how blogs as a new communication tool may potentially help cancer patients seek information and/or communication.
The information collected form this survey will be accessible only to the researchers. No personally identifiable information will be collected, and information will be presented in aggregate form. The survey will be collected on a server with SSL (Secure Sockets Layer) capabilities, which is one of the best providers of Internet security available, but there is always a risk that a third party may intercept the survey answers.
There are no foreseeable risks associated to this study. However, if you feel uncomfortable answering the survey questions, you may choose to skip a question or withdraw from the study at any time.........
Posted by: Sherin Permalink Source
Timing Of Radiation Treatments For Colon Cancer
The researchers, led by Bruce Boman, M.D., Ph.D., director of the Division of Genetic and Preventive Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia and at Jefferson's Kimmel Cancer Center and Dennis Leeper, Ph.D., professor of radiation oncology at Jefferson Medical College, say these results may have implications for treating patients with colon cancer, which is a tumor that frequently has mutations in a gene called APC.
They reported their findings this week at the 2006 annual meeting of the American Association for Cancer Research in Washington, D.C. (Stem Cell Number and Radiation Resistance During Repair in Colonic Crypts of APC Mice: Abstract no. LB-311).
Researchers have known that patients' colon tumors with APC mutations have an increased amount of survivin, a protein that halts the process of programmed cell death. This increase also appears to be associated with a rise in the number of stem cells that sit at the bottom of colonic crypts, tube-like structures that make up the lining of the intestine. Drs. Leeper and Boman wanted to see if there was a difference in stem cell number between normal mice and mice that carry a mutation in APC. To do this, they exposed both normal and mutant mice to radiation, testing their ability to repair the resulting DNA damage. They speculated that increased survivin in the mutant mice might enable more stem cells to survive and affect the response to radiation. The scientists asked if mice with an APC mutation, making them prone to develop colon cancer, are different from normal mice in radiation sensitivity and their ability to repair the damage. Normal cells can repair DNA damage from radiation, Dr. Leeper explains.........
Posted by: Sue Permalink Source
Pain Medications Prevent Cancer
These study findings were reported in the recent annual meeting of the American Association for Cancer Research in Washington, D.C. The researchers have found significant chemopreventive effects against breast cancer with the regular use of Cox-2 inhibitors and other non-steroidal anti-inflammatory drugs. The study was conducted by Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine.
Dr. Randall Harris and colleagues conducted a large case-control study of Cox-2 inhibitors and studied their impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. COX-2 inhibitors are non-steroidal, anti-inflammatory drugs that specifically block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.
Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.........
Posted by: Janet Permalink Source
Feb 20, 2006
Treatment Standard For Elderly With Colon Cancer
The analysis focused on nearly 4,000 colon cancer patients who had been enrolled in four large-scale clinical trials that began in the 1990s nationwide and in Europe. The four studies helped establish the value against colorectal cancer of the chemotherapy regimen known as FOLFOX4, a combination of the standard anticancer drugs 5-fluorouracil (5-FU), leucovorin and the new drug oxaliplatin.
"These four studies redefined the treatment standards for colorectal cancer in the United States," said Dr. Richard Goldberg, professor of medicine in UNC's School of Medicine and chief of hematology-oncology at UNC Health Care. "At the time the trials were designed, FOLFOX was experimental; now it is standard."
Goldberg also is associate director of clinical research at UNC Lineberger Comprehensive Cancer Center.
He presented the findings of his review Jan. 25 to a gastrointestinal cancer symposium in San Francisco convened by the American Society of Clinical Oncology, the American Society of Radiation Oncology, the American Gastroenterological Association and the Society of Surgical Oncology.
Although the average age of people nationwide with colorectal cancer is 67 years, individuals older than age 70 accounted for only about 16 percent of patients enrolled in the four FOLFOX clinical trials.
According to Goldberg, this shows that older patients are under-enrolled in clinical trials and also explains why doctors who must manage older colon cancer patients "are not as certain what to do for them as they are for the population that is most represented in clinical trials: those under the age of 65."
In our aging society, an increasing number of people with colorectal cancer are going to be in their seventies and eighties, Goldberg said. "So doctors need to sort out what to do for these patients," he added.
Feb 17, 2006
Physical Activity And Colon Cancer Risk
Some researchers have previously theorized that it might also inhibit colon cancer. Over forty epidemiologic studies have examined the association with varying results. Many observed a reduction in colon cancer risk for people reporting high levels of activity, compared to those who did not. Several studies have shown a stronger inverse relationship for men, compared to women. Other studies have found no association at all for women.
Researchers led by Brook A. Calton, from the University of California-San Francisco, conducted a prospective study of a large cohort of post-menopausal women in the United States. Using the Breast Cancer Detection Demonstration Project Follow-up Study, they collected information about physical activity and colon cancer cases for 31,783 women. There were 243 cases of colon cancer during the ten-year study period from 1989 to 1998.
Researchers analyzed the data for physical activity for all women, and observed no association between physical activity and the subsequent risk of colon cancer. "The results of this large prospective cohort study among women do not support the hypothesis that physical activity is related to a lower incidence of colon cancer," the authors report.
Feb 13, 2006
Do You Read All Of Our Medical Blogs?
Breast cancer blog: Breast cancer blog is run by Janet and colleagues. Latest post from this breast cancer blog reads as follows: More Likely To Be Diagnosed With Breast Cancer In Summer - [imgl]/images/blog/summer-woman-654580.jpg[/imgl]Scientists have observed that woman generally tend to have diagnosis of breast cancer in spring and summer months compared rest of the year. They believe that this is due to the fact that women are more aware of their body in these months due to skimpier clothes in the warmer weather. This would make them more aware of their body and in turn they examined themselves more often.......
Lung cancer blog: Lung cancer blog is run by Scott and colleagues. Latest post from this lung cancer blog reads as follows: Minimally Invasive Surgery For Lung Cancer - Video-assisted thoracoscopic surgery (VATS), which is a form of minimally invasive surgical procedure for lung cancer has been shown to be as effective as open surgery with a low risk of complications and high survival rates when performed by experienced thoracic surgeons.
Colon cancer blog: Colon cancer blog is run by Sue and colleagues. Latest post from this cancer blog post reads as follows: Cancer Death Rate Finally Falls - For the first time in 70 years the cancer death rate has actually declined in the United States. This may be an indication that we are winning the war on cancer and this point in time may very well represent a dramatic turning point in the history of cancer...............
Prostate cancer blog: Prostate cancer blog is run by Mark and colleagues. Latest post from this prostate cancer blog reads as follows: Inflammatory Reaction And Hormone Resistance - In a study led by Michael Rosenfeld and David Rose at the University of California, San Diego, the researchers have found that cell cultures that so-called macrophages--components of the innate immune system that drive inflammatory reactions--physically interact with prostate cancer cells. That interaction, in turn, reverses the activity of hormone receptors in cancer cells that respond to androgens, such as testosterone, leading to shifts in the expression of other genes. The study's co-first authors were Ping Zhu and Sung Hee Baek, also of UCSD.......
We have a diabetes watch blog as well and this is run by JoAnn and colleagues. The latest post from this diabetes watch blog reads as follows: Hormonal Therapy Of Prostate Cancer Could Be Lead To Diabetes, Heart Disease - Hormone therapy is the first best option for patients with recurrent prostate cancer. Hormone therapies is usually used to block testosterone production in an effort to halt or slow the growth of the tumor. New research suggests that hormone therapy may have its own toll. Hormone therapy may put these men at increased risk for developing insulin resistance and elevated blood sugar levels. This in turn can affect heart health...............
Heart watch blog: Heart watch blog is run by Daniel and colleagues. The latest post from this heart watch blog reads as follows: Hormonal Therapy Of Prostate Cancer Could Be Lead To Diabetes, Heart Disease - Hormone therapy is the first best option for patients with recurrent prostate cancer. Hormone therapies is usually used to block testosterone production in an effort to halt or slow the growth of the tumor. New research suggests that hormone therapy may have its own toll. Hormone therapy may put these men at increased risk for developing insulin resistance and elevated blood sugar levels. This in turn can affect heart health...............
Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. The latest post from this cancer blog reads as follows: Inflammatory Reaction And Hormone Resistance - In a study led by Michael Rosenfeld and David Rose at the University of California, San Diego, the researchers have found that cell cultures that so-called macrophages--components of the innate immune system that drive inflammatory reactions--physically interact with prostate cancer cells. That interaction, in turn, reverses the activity of hormone receptors in cancer cells that respond to androgens, such as testosterone, leading to shifts in the expression of other genes. The study's co-first authors were Ping Zhu and Sung Hee Baek, also of UCSD...............
Older Blog Entries 1 2 3 4 5
Colorectal cancer is a malignant tumor that arises from the inner wall of the large intestine or rectum. Colorectal cancer is the third commonest cancer diagnosed in the United States. Each year over 100,000 people are diagnosed with colorectal cancer in the United States. Most, of these cancers develop from growths in the colon called polyps. Removal of these polyps can prevent colon cancer.
Medicineworld.org: Archives of colon-cancer-blog
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.